CBR-470-2, a glycine-substituted analog, can activate NRF2 signaling. CBR-470-2 can be used for the research of modulation glycolysis In Vitro CBR-470-2 (1-10 μM; 24 h) increases transcript levels of the NRF2-responsive genes NQO1 and HMOX1 in epidermal keratinocytes and dermal fibroblasts. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo CBR-470-2 (50 mg/kg; p.o. twice daily for 10 d) induces activation of NRF2 signaling in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Balb/C mice (5-week old) are exposed to UVB Dosage: 50 mg/kg Administration: P.o. twice daily for 10 days Result: Resulted in comparable beneficial effects on erythema histological scores and total wounded area. Decreased epidermal thickness in response to UV exposure. Form:Solid IC50& Target:NRF2